Cartesian Therapeutics, Inc.
جودة البيانات: 100%
RNAC
Nasdaq
Manufacturing
Chemicals
KWD 5.98
▼
KWD 0.20
(-3.24%)
القيمة السوقية: 165.68 M
السعر
KWD 6.25
القيمة السوقية
165.68 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue declined -57.42% annually over 5 years
Negative free cash flow of -79.40 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 35.39%
Capital intensive — 194.99% of revenue goes to capex
النمو
Revenue Growth (5Y)
-57.42%
أقل من متوسط القطاع (1.82%)
Revenue (1Y)-92.81%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
N/A
ROIC-30.81%
Net Margin-4658.63%
Op. Margin-5127.10%
الأمان
Debt / Equity
N/A
Current Ratio10.67
Interest CoverageN/A
التقييم
PE (TTM)
-1.27
أعلى من متوسط القطاع (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.3 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.3 |
| Net Margin % | -4658.6 | -41.5 |
| Rev Growth 5Y % | -57.4 | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
7 محللين
Buy
الحالي
KWD 5.98
المستهدف
KWD 35.57
KWD 16.00
KWD 39.00
KWD 44.00
التوقعات
مكرر الربحية المستقبلي
-3.54
ربحية السهم المستقبلية
-KWD 1.69
الإيرادات المقدّرة
613,860.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.69
-KWD 1.69 – -KWD 1.69
|
613,860.0 | 1 |
| FY2026 |
-KWD 2.15
-KWD 2.15 – -KWD 2.15
|
588,560.0 | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.68
-KWD 0.68 – -KWD 0.68
|
149,890.0 | 1 |
| 2026 Q1 |
-KWD 0.70
-KWD 0.70 – -KWD 0.70
|
149,890.0 | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.79 | -KWD 2.71 | -242.6% |
| Q32025 | -KWD 0.63 | -KWD 0.73 | -16.0% |
| Q22025 | -KWD 0.65 | -KWD 0.77 | -18.8% |
| Q12025 | -KWD 0.71 | -KWD 0.65 | +7.9% |
ETFs Holding This Stock
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -92.81% | Revenue Growth (3Y) | -67.20% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -57.42% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2.80 M | Net Income (TTM) | -130.30 M |
| ROE | N/A | ROA | -34.22% |
| Gross Margin | N/A | Operating Margin | -5127.10% |
| Net Margin | -4658.63% | Free Cash Flow (TTM) | -79.40 M |
| ROIC | -30.81% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 10.67 |
| Interest Coverage | N/A | Asset Turnover | 0.01 |
| Working Capital | 133.46 M | Tangible Book Value | -84.01 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.27 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 59.24 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -47.92% | ||
| Market Cap | 165.68 M | Enterprise Value | 22.30 M |
| Per Share | |||
| EPS (Diluted TTM) | -5.02 | Revenue / Share | 0.11 |
| FCF / Share | -3.00 | OCF / Share | -2.79 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 194.99% | FCF Conversion | 60.93% |
| SBC-Adj. FCF | -89.47 M | Growth Momentum | -35.39 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.80 M | 38.91 M | 26.00 M | 110.78 M | 85.08 M |
| Net Income | -130.30 M | -77.42 M | -219.71 M | 35.38 M | -25.69 M |
| EPS (Diluted) | -5.02 | -4.49 | -1.66 | 0.10 | -0.22 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -143.41 M | -43.90 M | -86.42 M | 14.54 M | -4.60 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 58.03 M | 45.11 M | 71.84 M | 72.38 M | 68.74 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | 0.0 | 2.83 M | 3.03 M | 2.84 M |
| Income Tax | -9.19 M | 287,000.0 | -19.00 M | -609,000.0 | 15.97 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 296.41 M | 435.02 M | 305.05 M | 165.89 M | 159.88 M |
| Total Liabilities | 422.65 M | 441.83 M | 444.68 M | 72.06 M | 137.36 M |
| Shareholders' Equity | -126.24 M | -6.80 M | -440.18 M | 93.83 M | 22.52 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 125.14 M | 212.61 M | 76.91 M | 106.44 M | 114.06 M |
| Current Assets | 129.28 M | 216.63 M | 90.73 M | 148.14 M | 144.44 M |
| Current Liabilities | 14.94 M | 22.98 M | 68.21 M | 25.08 M | 72.25 M |
{"event":"ticker_viewed","properties":{"ticker":"RNAC","listing_kind":"stock","pathname":"/stocks/rnac","exchange":"Nasdaq","country":"US"}}

